Identification of a feedback loop involving β-glucosidase 2 and its product sphingosine sheds light on the molecular mechanisms in Gaucher disease

Sophie Schonauer‡, Heinz G. Körshens‡, Anke Penno‡, Andreas Rennhack‡, Berndadette Breiden†, Konrad Sandhoff‡, Katharina Gutbrod‡‡, Peter Dörmann‡‡, Diana N. Raju¶, Per Haberkant¶¶, Mathias J. Gerl¶¶¶, Britta Brügger§, Hila Zigdon¶¶, Ayelet Vardi¶¶, Anthony H. Futerman‡‡‡, Christoph Thiele¶¶¶, and Dagmar Wachten¶¶¶¶

From the ‡Minerva Max Planck Research Group, Molecular Physiology, and the ‡Department of Molecular Sensory Systems, Center of Advanced European Studies and Research (caesar), 53175 Bonn, Germany, the ³Department of Cell Biology of Lipids, LIMES Institute, University of Bonn, Bonn, Germany, the ⁴LIMES Institute, c/o Kekulé-Institute, University of Bonn, 53115 Bonn, Germany, the ⁵Institute of Molecular Physiology and Biotechnology of Plants, University of Bonn, 53115 Bonn, Germany, the ⁶Proteomic Core Facility, EMBL Heidelberg, 69117 Heidelberg, Germany, the ⁷Biochemie-Zentrum (BZH), Ruprecht-Karls-University Heidelberg, 69120 Heidelberg, Germany, the ⁸Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 76100, Israel, and the ⁹Institute of Innate Immunity, University Hospital, University of Bonn, 53127 Bonn, Germany

Edited by George M. Carman

The lysosomal acid β-glucosidase GBA1 and the non-lysosomal β-glucosidase GBA2 degrade glucosylceramide (GlcCer) to glucose and ceramide in different cellular compartments. Loss of GBA2 activity and the resulting accumulation of GlcCer results in male infertility, whereas mutations in the GBA1 gene and loss of GBA1 activity cause the lipid-storage disorder Gaucher disease. However, the role of GBA2 in Gaucher disease pathology and its relationship to GBA1 is not well understood. Here, we report a GBA1-dependent down-regulation of GBA2 activity in patients with Gaucher disease. Using an experimental approach combining cell biology, biochemistry, and mass spectrometry, we show that sphingosine, the cytotoxic metabolite accumulating in Gaucher cells through the action of GBA2, directly binds to GBA2 and inhibits its activity. We propose a negative feedback loop, in which sphingosine inhibits GBA2 activity in Gaucher cells, preventing further sphingosine accumulation and, thereby, cytotoxicity. Our findings add a new chapter to the understanding of the complex molecular mechanism underlying Gaucher disease and the regulation of β-glucosidase activity in general.

Gaucher disease is one of the most common lysosomal storage disorders in humans. It results from a deficiency in the activity of the lysosomal enzyme, acid β-glucosidase GBA1 (also termed GCase) (1). So far, more than 200 different mutations in the GBA1 gene have been identified in Gaucher patients (2), all leading to the loss of enzyme activity, resulting in GlcCer accumulation in the lysosome. This is predominantly evident in tissue macrophages, which turn into massively enlarged “Gaucher” cells, causing an up to 25-fold increase in organ size (organomegaly) of liver and spleen (3, 4). Gaucher disease has been classified into three major subtypes, namely types I, II, and III (4). Type I is the most common, with patients displaying organomegaly of liver and spleen and defects in lung and bone marrow. Type II patients have the acute infantile neuronopathic form, characterized by severe neurological defects and an early onset of disease. These patients usually die within the first 2–3 years of life, whereas type III patients develop a slowly progressive neuropathology. It has been assumed that residual GBA1 activity might help to predict the severity of Gaucher disease, but the severity of the disease even differs between patients carrying the same mutation (5). Thus, little genotype-phenotype correlation has been established so far.

How the accumulation of GlcCer in the lysosomes causes the complex Gaucher pathology is not well understood. Moreover, deficiency of GBA1 also causes accumulation of glucosylsphingosine (GlcSph) (6–8), which may also contribute to the neurological manifestation (9, 10). It has been proposed that in Gaucher cells, both, Glicer and GlcSph, leave the lysosome, becoming substrates for the non-lysosomal β-glucosidase GBA2 (11, 12), which resides at the cytoplasmic surface of the ER and cis-Golgi (13). In turn, GBA2 might hydrolyze GlcCer to glucose and ceramide and GlcSph to glucose and sphingosine (11, 12). Ceramide can be further broken down to sphingosine and a fatty acid by neutral ceramidases. Hence, on the back-

The work was supported in part by a grant from the Fritz Thysen Foundation and by the Deutsche Forschungsgemeinschaft Grants SF6845 (to D. W., C. T., and P. D.) and TRR88 (to C. T., B. B., and K. S.), and a grant from the Excellence Cluster ImmunoSensation, Bonn (to D. W.). The authors declare that they have no conflicts of interest with the contents of this article.

1 Present address: Lipotype GmbH, Tatzberg 47, 01307 Dresden, Germany.
2 A Joseph Meyerhoff Professor of Biochemistry at the Weizmann Institute of Science.
3 To whom correspondence should be addressed: Center of Advanced European Studies and Research (caesar), Ludwig-Erhard-Allee 2, 53175 Bonn, Germany; Tel.: 49-228-9656-311; Fax: 49-228-9656-9311; E-mail: dagmar.wachten@caesar.de.

4 The abbreviations used are: GlcSph, glucosylsphingosine; CBE, conduritol B epoxide; FTY720, 2-amino-2-[2-(4-oxyclophenyl)ethyl]propane-1,3-diol; GBA1, acid β-glucosidase; GBA2, non-lysosomal β-glucosidase; GlcCer, glucosylceramide; NB-DNJ, N-butyl-deoxynojirimycin; S1P, sphingosine 1-phosphate; 4-MUG, 4-methyl-umbelliferyl β-o-glucopyranoside; HAP1, human fibroblast-like cells; IPTG, isopropyl β-o-thiogalactopyranoside; mPic, mammalian protease inhibitor cocktail; Sph, sphingosine.
GA2 in Gaucher disease

ground of reduced GBA1 activity in lysosomes and leakage of its substrates outside the lysosomes, GBA2 activity might lead to an increased generation of sphingosine at the ER and cis-Golgi. It has been proposed that sphingosine is the cytotoxic metabolite that causes some of the defects associated with Gaucher disease, at least upon its chronic accumulation (12). In fact, deletion of GBA2 rescued some of the pathologies by reducing the accumulation of sphingosine (12). This is in line with our previous findings, indicating that GBA2 activity is altered when GBA1 activity is lost (13).

Here, we set out to investigate the role of GBA2 in Gaucher disease. We demonstrate that GBA2 activity depends on GBA1 activity, but not vice versa. GBA2 activity is inhibited by the cytotoxic metabolite sphingosine, which directly binds to GBA2. Our results suggest a negative feedback loop in Gaucher cells, in which sphingosine prevents its excessive accumulation by inhibiting the activity of GBA2 through direct binding.

Results

GA2 activity is down-regulated in the absence of GBA1 activity

Based on our previous results (13), we analyzed GBA2 activity in fibroblasts from different types of Gaucher patients and in control fibroblasts using a fluorescence-based activity assay (13) that contains the artificial and water-soluble substrate 4-methylumbelliferyl-β-D-glucopyranoside (4-MUG) and determines GBA1 activity at pH 4 and GBA2 activity at pH 6. For each pH, we included the GBA1-specific inhibitor conduritol B epoxide (CBE) and the GBA2-inhibitor N-butyldeoxynojirimycin (NB-DNJ) at concentrations that only inhibit the respective enzyme (13). As expected, GBA1 activity was almost absent in hypotonic lysates from Gaucher fibroblasts, with residual activities of 8, 2.6, and 5.6% for types I, II, and III, respectively (Fig. 1A). In line with our earlier findings (13), GBA2 activity in all types of Gaucher fibroblasts was decreased to around 60% of the activity in control cells (Fig. 1B). There was no difference in GBA2 activity between fibroblasts derived from patients with different genotypes and phenotypes, indicating that GBA2 activity is reduced independent of the Gaucher genotype and phenotype. To confirm this result, we measured GBA2 activity in two independent GBA1-deficient human fibroblast-like cell lines (HAP1) generated via CRISPR/Cas9 (Fig. 1, C and D). The first GBA1-deficient HAP1 cell line (HZGH002786c001, abbreviated #001) contains a 479-bp insertion in exon 6 of the GBA1 gene and the second GBA1-deficient HAP1 cell line (HZGH002786c010, abbreviated #010) contains a 1-bp insertion in exon 6, both resulting in a frameshift and, therefore, in gene silencing. In both cell lines, GBA1 activity was absent and GBA2 activity was reduced by ~40% (Fig. 1, C and D). As a control, we determined the GBA1 activity in two independent GBA2-deficient human fibroblast-like cell lines generated via CRISPR/Cas9 (Fig. 1, E and F). However, in the absence of GBA2 activity, GBA1 activity remained largely unchanged (Fig. 1, E and F). In summary, GBA2 activity is down-regulated in the absence of GBA1 activity, but not vice versa.

To study whether the decrease in GBA2 activity is due to a change in GBA2 expression, we analyzed GBA2 mRNA and protein expression. The mRNA expression in dermal fibroblasts from different types of Gaucher and control patients was determined using quantitative real-time PCR (Fig. 1, G and H). For both, GBA1 and GBA2, there was no significant difference in relative mRNA expression between control fibroblasts and Gaucher fibroblasts from the different genetic backgrounds (Fig. 1, G and H). Protein expression in dermal fibroblasts from Gaucher and control patients was analyzed by Western blotting (Fig. 1I). The GBA1 protein level in fibroblasts from Gaucher patients was significantly reduced compared with control cells with GBA1 expression being lowest in fibroblasts from type II patients (Fig. 1, J and K). However, GBA2 protein expression remained largely unchanged in control and Gaucher fibroblasts (Fig. 1, J and K). Thus, down-regulation of GBA2 activity in the absence of GBA1 activity is not due to a decrease in GBA2 mRNA or protein expression.

GA2 activity depends on GBA1 activity in vitro and in vivo

To gain mechanistic insight how GBA1 controls GBA2 activity, we analyzed whether blocking GBA1 activity is sufficient to reduce GBA2 activity. Here, we applied a pharmacologic approach. Control human fibroblasts were treated with 25 μM CBE for 48 h to block GBA1 activity (Fig. 2, A and B). Of note, this CBE concentration does not block GBA2 activity (13). GBA1 activity was dramatically reduced in CBE-treated cell lysates compared with the non-treated controls (Fig. 2A). In line with our findings from Gaucher and GBA1-deficient fibroblasts, GBA2 activity in CBE-treated cells was reduced to ~39% of the activity in non-treated control cells (Fig. 2B). These results demonstrate that blocking GBA1 activity is sufficient to reduce GBA2 activity. We also tested this experimental paradigm in HEK293 cells transiently overexpressing mGBA2 and endogenously expressing GBA1 (Fig. 2, C and D). Again, full block of GBA1 activity (Fig. 2C) reduced GBA2 activity to ~46% of the activity in non-treated control cells (Fig. 2D). As a control, we incubated embryonic fibroblasts from GBA1-deficient mice with 25 μM CBE for 48 h (Fig. 2, E and F), which allows to measure CBE-dependent effects on GBA2 activity independent of a change in GBA1 activity. GBA1-deficient embryonic fibroblasts lack GBA1 activity (Fig. 2E), and the activity of GBA2 remained unchanged in these cells (Fig. 2F). In addition, we analyzed GBA2 protein expression in CBE-treated HEK293 cells overexpressing mGBA2, but there was no difference between treated and non-treated cells (Fig. 2, G and H). We also performed the experiments vice versa in HEK293 cells overexpressing mGBA2 by blocking GBA2 activity with 2 μM NB-DNJ for 48 h (Fig. 2, I and J). Whereas GBA2 activity was completely abolished in NB-DNJ-treated cells (Fig. 2I), GBA1 activity remained unchanged (Fig. 2I). Thus, our results suggest that GBA1 activity regulates GBA2 activity, but not vice versa, and that the regulation occurs independently of changes in protein expression.

Next, we analyzed the time course of the GBA1-dependent regulation of GBA2 activity. GBA1 activity was blocked with 25 μM CBE for 10 min up to 48 h (Fig. 2K). GBA1 activity was significantly reduced after 3 h of CBE treatment and was max-
GBA2 in Gaucher disease

Figure 1. GBA2 activity is down-regulated in the absence of GBA1. A, GBA1 activity in fibroblasts from control and Gaucher patients. GBA1 activity was measured in hypotonic lysates from control (ctrl) and Gaucher fibroblasts (types I, II, and III) using 1.67 mM 4-MUG as a substrate. Data were normalized to the control. 100% GBA1 activity: 32.3 pmol/μg of protein/h. B, see A for GBA2 activity. 100% GBA2 activity: 0.9 pmol/μg of protein/h. C, GBA1 activity in wild-type (WT) and GBA1-deficient (KO) HAP1 fibroblasts. GBA1 activity was measured in hypotonic lysates using 1.67 mM 4-MUG; two independent GBA1-deficient cell lines (#001 and #010) were analyzed. Data were normalized to wild-type cells. 100% GBA1 activity: 8.9 pmol/μg of protein/h. D, see C for GBA2 activity. 100% GBA2 activity: 2.2 pmol/μg of protein/h. E, see C for wild-type (WT) and GBA2-deficient (KO) HAP1 fibroblasts. GBA1 activity: 7.4 pmol/μg of protein/h. F, see E for GBA2 activity. 100% GBA2 activity: 2.2 pmol/μg of protein/h. G, GBA1 mRNA expression in control and Gaucher patients (types I, II, and III) analyzed by quantitative PCR. Data were normalized to the control. H, see G for GBA2. I, GBA1 and GBA2 protein in control and Gaucher patients (types I and II). Hypotonic lysates were subjected to Western blotting analysis using GBA1- and GBA2-specific antibodies. Calnexin was used as a loading control. J, quantification of GBA1 protein expression levels, normalized to the loading control and then to control samples. For quantification, all GBA1 bands were taken into account. K, see J for GBA2. All data are represented as mean ± S.D.; n are indicated in parentheses.

GBA2 can be obtained by intraperitoneal (i.p.) injection of low doses of CBE (14, 15). Eight-day-old 60Hsd mice were injected with 25–100 mg of CBE/kg/day for 10 days. After treatment, mice were sacrificed and the brain was dissected. GBA1 and GBA2 activities were assayed in hypotonic brain lysates from CBE-treated and control mice. All tested CBE concentrations blocked GBA1 activity by >85% (Fig. 3A) (15). In line with our earlier findings, GBA2 activity was also reduced at all CBE concentrations tested (Fig. 3B). Of note, at high concentrations, CBE also inhibits the activity of GBA2 (13, 16). The final con-
concentration of CBE in the brain is difficult to estimate. However, the reduction in GBA2 activity was similar, independent of the applied CBE dose (Fig. 3B), indicating that the reduction of GBA2 activity is GBA1-dependent and not due to a direct inhibition by CBE. As a control, we also analyzed GBA2 protein expression in CBE-treated mouse brains compared with controls (Fig. 3, C and D). However, GBA2 protein expression was not affected by CBE treatment. Thus, the GBA1-dependent regulation of GBA2 activity occurs not only in vitro in isolated cells in culture, but also seems to be present in vivo, independent of changes in protein expression levels.

**Investigating the underlying mechanism**

Previous studies have reported an increase of GBA2 activity in cells from Gaucher patients (17, 18). This is in contrast to our findings, which is why we first performed additional experi-
GBA2 activity was measured in hypotonic brain lysates from control (PBS) and CBE-injected mice using 1.67 mM 4-MUG as a substrate. Data were normalized to the control.

100% GBA1 activity: 6.2 pmol/μg of protein/h. B, see A for GBA2 activity. 100% GBA2 activity: 84.6 pmol/μg of protein/h. C, GBA1 and GBA2 protein expression in brain from control (PBS) and CBE-injected mice. Hypotonic lysates were subjected to Western blotting analysis using GBA1- and GBA2-specific antibodies. Calnexin was used as a loading control. A representative blot for one CBE concentration and three different animals is shown. CHO cells stably expressing GBA1 and GBA2 were used as positive control. D, quantification of GBA2 protein expression levels in brain from CBE-injected mice (data from H), normalized to control (PBS) samples. All data are represented as mean ± S.D.; n are indicated in parentheses.

GBA2 activity is also reduced in vivo in a pharmacological Gaucher mouse model. A, GBA1 activity in brain from CBE-injected mice. GBA1 activity was measured in hypotonic brain lysates from control (PBS) and CBE-injected mice using 1.67 mM 4-MUG as a substrate. Data were normalized to the control. 100% GBA1 activity: 261.7 pmol/μg of protein/h. B, see A for GBA2 activity. 100% GBA2 activity: 206.0 pmol/μg of protein/h.

Figure 3. GBA2 activity is also reduced in vivo in a pharmacological Gaucher mouse model. A, GBA1 activity in brain from CBE-injected mice. GBA1 activity was measured in hypotonic brain lysates from control (PBS) and CBE-injected mice using 1.67 mM 4-MUG as a substrate. Data were normalized to the control. 100% GBA1 activity: 261.7 pmol/μg of protein/h. B, see A for GBA2 activity. 100% GBA2 activity: 206.0 pmol/μg of protein/h. C, GBA1 and GBA2 protein expression in brain from control (PBS) and CBE-injected mice. Hypotonic lysates were subjected to Western blotting analysis using GBA1- and GBA2-specific antibodies. Calnexin was used as a loading control. A representative blot for one CBE concentration and three different animals is shown. CHO cells stably expressing GBA1 and GBA2 were used as positive control. D, quantification of GBA2 protein expression levels in brain from CBE-injected mice (data from H), normalized to control (PBS) samples. All data are represented as mean ± S.D.; n are indicated in parentheses.

GBA2 activity depends on GBA1 activity. A, GBA1 activity in CBE-treated human fibroblasts. GBA1 activity was measured in hypotonic lysates from control (ctrl) and fibroblasts treated with 25 μM CBE for 48 h using 1.67 mM 4-MUG as a substrate. Data were normalized to the control. 100% GBA1 activity: 27.0 pmol/μg of protein/h. B, see A for GBA2 activity. 100% GBA2 activity: 3.5 pmol/μg of protein/h. C, GBA1 and GBA2 protein expression in control (DMSO-treated) and CBE-treated (CBE, 25 μM, 48 h) CHO cells transiently over-expressing GBA2. Hypotonic lysates were subjected to Western blotting analysis using GBA1- and GBA2-specific (anti-HA) antibodies. Tubulin was used as a loading control for HEK293 cells. CHO cells stably expressing GBA1 and GBA2 were used as positive control. H, quantification of GBA1 and GBA2 protein expression levels in CBE-treated cells (data from H), normalized to control samples. I, GBA1 activity in NB-DNJ-treated HEK293 cells transiently over-expressing GBA2. GBA1 activity was measured in hypotonic lysates from control and HEK293 cells treated with 2 μM NB-DNJ for 48 h using 1.67 mM 4-MUG as a substrate. Data were normalized to the control. 100% GBA1 activity: 26.3 pmol/μg of protein/h. J, see I for GBA2 activity. 100% GBA2 activity: 195.8 pmol/μg of protein/h. K, time course of the GBA1-dependent regulation of GBA2 activity in CHO cells stably over-expressing mGBA2. Cells were incubated with 25 μM CBE for 10 min up to 48 h. β-Glucosidase activity was analyzed in hypotonic cell lysates in the presence of 1.67 mM 4-MUG. 100% GBA1 activity: 7.4 pmol/μg of protein/h. 100% GBA2 activity: 405.0 pmol/μg of protein/h. All data are represented as mean ± S.D.; n are indicated in parentheses.

GBA2 in Gaucher disease

Deficiency of GBA1 in Gaucher patients causes the accumulation of two sphingolipids, GlcCer and GlcSph (7, 12). It has been proposed that under chronic conditions, both, GlcCer and GlcSph, spill over from the lysosome into the cytoplasm, thereby becoming substrates for GBA2, which degrades GlcCer and GlcSph to glucose and ceramide or sphingosine, respectively (12). We determined the levels of sphingosine and GlcSph in wild-type and GBA1-deficient fibroblasts after separating...
the membrane and cytosolic fraction (Fig. 4, A and B). Both sphingosine and GlcSph levels displayed an elevating trend in membrane fractions of Gaucher disease or GBA1-deficient fibroblasts, respectively (Fig. 4, A and B).

We therefore hypothesized that cells accumulating GlcCer and GlcSph, due to a loss of GBA1 activity, might have developed a mechanism, whereby GBA2 activity is diminished to avoid a cytotoxic accumulation of sphingosine or GlcSph. The simplest scenario that could be envisioned in this regard is a direct regulation of GBA2 activity by these metabolites. To test this hypothesis, we first analyzed whether the GBA2 activity is sensitive to sphingosine. CHO cells stably overexpressing mGBA2 were incubated with 20 μM sphingosine complexed to BSA, and GBA1 and GBA2 activity was measured (Fig. 4, C and

---

**GBA2 in Gaucher disease**

---

**Figures:**

- **A:** Graph showing lipid levels in control (ctrl) and treated (I, II, III) conditions.
- **B:** Graph showing glucosyl/sphingosine levels in WT and KO conditions.
- **C:** Graph showing GBA1 activity in control and 20 μM sphingosine conditions.
- **D:** Graph showing GBA2 activity in control and 20 μM sphingosine conditions.
- **E:** Graph showing GBA2 activity in WT and GBA1-KO conditions.
- **F:** Graph showing GBA1 activity in control and 20 μM sphingosine conditions.
- **G:** Graph showing GBA2 activity in control and 20 μM sphingosine conditions.
- **H:** Graph showing ceramide levels in WT and KO conditions.
- **I:** Graph showing sphingobases in control (DMSO) and treated (Carmofur) conditions.
- **J:** Graph showing GBA2 activity in control and treated conditions with and without GBA1.
- **K:** Graph showing GBA2 activity in control and treated conditions with and without Carmofur.
The activity of both, GBA1 and GBA2, was significantly reduced to around 27% and 46% of the non-treated samples, respectively (Fig. 4, C and D). However, this experimental set-up does not allow to conclude whether both GBA1 and GBA2 are sensitive to sphingosine, as a sphingosine-dependent reduction of GBA1 activity would be sufficient to reduce GBA2 activity. Thus, to study the effect of sphingosine on GBA2 in a GBA1-independent manner, we incubated embryonal fibroblasts from GBA1-deficient mice with 20 \( \mu M \) sphingosine (Fig. 4E). Sphingosine treatment reduced the GBA2 activity in wild-type fibroblasts to around 62% compared with the non-treated samples (Fig. 4E). Likewise, in GBA1-deficient cells, sphingosine further reduced the residual GBA2 activity to only 6% compared with 14% in the non-treated control (Fig. 4E). Thus, the activity of GBA1, as demonstrated before (20, 21), but also GBA2, is sensitive to sphingosine. To investigate whether the sphingosine-dependent change in GBA2 activity only occurs in intact cells or also in an in vitro system, we prepared hypotonic lysates from mouse brain and incubated them with 20 \( \mu M \) sphingosine for 1.5 h before performing the assay. Both, the activity of GBA1 and GBA2, were reduced after sphingosine treatment compared with control conditions (Fig. 4, F and G). To determine whether decreasing the levels of sphingosine reverses inhibition of GBA2 activity, we incubated wild-type and GBA1-deficient cells with the ceramidase inhibitor carmofur.

In the presence of carmofur, ceramide levels were increased in the presence of the drug, whereas levels of sphingobases were reduced (Fig. 4, H and I). In wild-type cells, carmofur had no effect on GBA2 activity. However, in GBA1-deficient cells, where GBA2 activity is reduced, the inhibition was reversed in the presence of carmofur (Fig. 4J). Carmofur had no direct effect on GBA2 activity when adding the drug to protein lysates in the assay (Fig. 4K).

To further investigate whether sphingosine exerts a direct effect on GBA2 or whether other cellular components indirectly mediate the inhibition of sphingosine on GBA2 activity, we expressed mGBA2 in Escherichia coli (Fig. 5A, inset). Of note, E. coli does not display any GBA1 activity (Fig. 5A), as shown by measuring \( \beta \)-glucosidase activity at pH 4. Thus, CBE was omitted in this assay. At pH 6 after IPTG induction, bacterial lysates over-expressing GBA2 displayed a prominent \( \beta \)-glucosidase activity that was blocked by NB-DNJ, demonstrating that GBA2 is expressed and active (Fig. 5A). The dose-response relationship of GBA2 activity to NB-DNJ at pH 6 in E. coli lysates displayed an IC_{50} of 14.5 \( \pm \) 2.7 nm (Fig. 5B), which is very similar to the IC_{50} determined in brain lysates (20.9 \( \pm \) 1.3 nm) (13). We then assayed the dose-response relationship of GBA2 for sphingosine in bacterial lysates. Sphingosine reduced the GBA2 activity with an IC_{50} of 25.0 \( \pm \) 0.2 \( \mu M \) (Fig. 5C). These results indicate that sphingosine directly inhibits GBA2.
ever, as described above, not only sphingosine, but also GlcSph accumulates in the absence of GBA1. In fact, GlcSph blocked GBA2 activity in a dose-dependent manner with an IC50 of 1.5 ± 0.1 µM (Fig. 5D). These results demonstrate that both toxic metabolites, GlcSph and sphingosine, inhibit GBA2 activity.

**Structural requirements for the sphingosine-dependent GBA2 inhibition**

Next, we tested other sphingolipid metabolites, structurally similar to sphingosine, regarding their ability to inhibit GBA2 activity. In the cell, sphingosine can be phosphorylated by sphingosine kinases to sphingosine-1-phosphate (S1P), a sphingoid messenger that controls multiple signaling pathways (22). S1P structurally differs from sphingosine, as it bears a negatively charged phosphate headgroup. S1P did not inhibit GBA2 activity, suggesting that the presence of a phosphate group disturbs the sphingosine-dependent inhibition of GBA2 activity (Fig. 5E). Fingolimod, or FTY720, is structurally related to sphingosine and is approved for the treatment of multiple sclerosis (23). FTY720 carries an octylphenyl group in its carbon tail, whereas sphingosine itself only bears a double bond at C4. In vivo, FTY720 is phosphorylated to form FTY720-phosphate, which resembles naturally occurring S1P and also binds to S1P-surface receptors of cells (24). FTY720-inhibited GBA2 activity with an IC50 value of 18.6 ± 0.4 µM (Fig. 5F). Next, we tested whether GBA2 is sensitive to the double bond in the alkyl chain of sphingosine or whether the saturated form of this sphingoid base, sphinganine, also exhibits an inhibitory effect. Sphinganine inhibits GBA2 with an IC50 of 30.6 ± 4.5 µM (Fig. 5G), suggesting that the presence of the double bond in the sphingoid alkyl chain is irrelevant for the inhibitory effect. Finally, we investigated whether GBA2 is sensitive to ceramide, a metabolite of sphingosine. However, ceramide (C6, C8, and C18) concentrations of up to 300 µM did not diminish GBA2 activity (Fig. 5, H–J). Thus, GBA2 seems to be only sensitive to non-acetylated sphingoid bases and their derivatives (GlcSph, sphingosine, sphinganine, and FTY720) and not to complex sphingolipids such as ceramides.

**Sphingosine reversibly blocks GBA2 activity and follows the rule of mixed-type inhibition**

To further characterize the sphingosine-dependent inhibition of GBA2 activity, we tested whether the block is reversible. Hypotonic lysates from bacteria expressing mGBA2 were pre-incubated with 25 µM sphingosine to evoke a half-maximal block of GBA2 activity or with DMSO as a control. After incubation, samples were diluted to a final sphingosine concentration of 3.85 µM. As a control, the sphingosine concentration was maintained at 25 µM. Treatment with 25 µM sphingosine reduced GBA2 activity to 50% of the control values, whereas almost full GBA2 activity was recovered when sphingosine was diluted to 3.85 µM (Fig. 6A). These results indicate that sphingosine reversibly blocks GBA2 activity. To determine the type of reversible inhibition (competitive, non-competitive, uncompetitive, and mixed inhibition), we incubated lysates from bacteria over-expressing mGBA2 with 25 µM sphingosine, competed the inhibitory effect by adding increasing amounts of 4-MUG, and analyzed the enzyme activities according to Michaelis-Menten (Fig. 6B). The maximal GBA2 activity (Vmax) in the presence of sphingosine was reduced to about 50% of the control activity (3.5 ± 0.1 versus 1.9 ± 0.1 relative fluorescence units/min, n = 3), pointing toward a non-competitive inhibition of sphingosine for GBA2 (Fig. 6B). Interestingly, the Km value was also shifted toward higher concentrations (171.3 ± 13.8 versus 304.0 ± 44.3 µM, n = 3) in the presence of sphingosine (Fig. 6B), which does not resemble the classic non-competitive inhibition model. Thus, our data suggest that the inhibition of GBA2 by sphingosine follows the rules of mixed inhibition, where the inhibitor can bind to an allosteric site of the enzyme if it has not bound its substrate yet, as well as to the enzyme-substrate complex. In this case, the Km value is increased, which resembles a lower affinity of the enzyme for its substrate, and Vmax is decreased.

**Discussion**

Here, we provide new insights into the regulation of GBA2 activity, in particular in Gaucher disease. We demonstrate that GBA2 activity depends on GBA1 activity, but not vice versa.
This mechanism applies generally, whenever GBA1 was pharmacologically blocked or genetically deleted, and in every in vitro and in vivo system that we tested, GBA2 activity was reduced. Other reports have also analyzed GBA2 activity in Gaucher disease, but demonstrated an increase in GBA2 activity in brain from GBA1-deficient mice and in fibroblasts from Gaucher disease patients (17, 18). These results are in contrast to our findings, and the reason for this discrepancy is not known. One explanation could be a difference in the experimental set-up, that is, how GBA2 activity was measured. Of note, our experiments and the experiments of others (17, 18) were all performed using the artificial, water-soluble substrate 4-MUG and not using the natural lipid GlcCer, making it difficult to directly transfer the molecular mechanisms to the in vivo situation. However, we have comprehensively analyzed GBA2 expression and activity in different in vitro and in vivo models. In none of them was GBA2 expression or activity higher in the absence of GBA1 activity, arguing against earlier findings as described above.

Our results indicate that GBA2 activity is inhibited by the cytotoxic metabolites sphingosine and GlcSph through direct binding. It has been proposed that sphingosine is generated by GBA2-dependent hydrolysis of GlcSph (12), whose levels are dramatically increased in Gaucher disease patients (6). GlcSph is generated by intralysosomal deacylation of the accumulating GlcCer and leaves the lysosome through a yet unknown mechanism (7). We first determined sphingosine levels in fibroblasts from control and Gaucher patients using mass spectrometry: sphingosine levels were slightly, albeit not significantly, increased in Gaucher fibroblasts with 1.3 ± 0.8 pmol/µg of protein in type I samples, 2.2 ± 2.3 pmol/µg of protein in type II samples, and 1.2 ± 0.51 pmol/µg of protein in type III samples compared with 1.4 ± 0.6 pmol/µg of protein in control cells. However, after separating the cells into a membrane and cytosolic fraction, sphingosine levels in the membrane fraction of all three types of Gaucher disease showed an elevating trend (Fig. 4A). The IC₅₀ of sphingosine for GBA2 is relatively high (25.0 ± 0.2 µm in mGBA2 expressed in bacteria). This concentration will never be reached in a cell without causing cell death. However, the local sphingosine concentration could be much higher than the global concentration in the cell. The concentration is presumably the highest in membranes directly at the site of production, which, according to the model, is close to GBA2. In line with this model, sphingosine accumulates preferably in the membranes of fibroblasts from Gaucher disease patients. To investigate the inhibition of GBA2 activity by sphingosine in a cellular context in more detail, a quantitative subcellular analysis of the sphingosine localization would be needed. Furthermore, GlcSph, as a cationic amphiphile, is highly cytotoxic, and its accumulation has also been attributed to the neuro-pathological defects in Gaucher disease (10, 25, 26). We demonstrate that not only sphingosine, but also GlcSph inhibits GBA2 activity. Of note, GBA1 activity has been shown to be inhibited by GlcSph (27). Thus, both cytotoxic metabolites inhibit GBA2 activity in a negative feedback loop to prevent further accumulation.

Direct inhibition of GBA2 activity is the most straightforward explanation to how sphingosine regulates GBA2 activity. However, sphingosine has other properties that could also affect GBA2 activity. Sphingosine is also a “bioactive lipid” (28). It either exerts its effect by directly binding to a protein and/or it indirectly changes the properties of cell membranes and, thereby, protein function. Sphingosine is a surface active agent, which attains its function due to its amphipathic structure: the headgroup carries an amino and two hydroxyl groups, which represent the hydrophilic part, whereas the carbon tail is highly hydrophobic. GBA2 activity is sensitive to detergents (13). Sphingosine forms micelles above a critical micelle concentration of 1 µm at pH 7.4 (29), close to the calculated IC₅₀ for GBA2. Palmitoylcarnitine is a fatty acyl ester with a critical micelle concentration of 10 µm (30) and contains similar surfactant properties as sphingosine without being involved in sphingolipid metabolism. Palmitoylcarnitine also showed a dose-dependent inhibition of GBA2 activity in bacterial lysates with an IC₅₀ of 31.31 ± 2.68 µm (data not shown). Thus, palmitoylcarnitine, but also sphingosine, might act as surfactants, forming protein-detergent complexes with GBA2, dissolving GBA2 from a membrane environment. We have shown that GBA2 is a membrane-associated protein at the cytoplasmic site of the ER and the cis-Golgi and that the interaction with the membrane, in particular with phospholipids, is crucial for GBA2 activity. After washing the protein off from the membrane, the activity is dramatically reduced, but can be restored when adding back membranes (13). Thus, dissolving GBA2 from the membrane by forming protein-detergent complexes would diminish its activity.

In conclusion, we reveal a sphingosine-dependent regulation of GBA2 activity, which occurs in the absence of GBA1 activity and might also occur in Gaucher disease. Our results add a new chapter to the understanding of the molecular mechanism underlying Gaucher disease pathology, presenting new ideas for the therapy of this severe lysosomal storage disorder.

**Experimental procedures**

**Constructs**

The open reading frame of mouse GBA2 (NM_172692) or mGBA1 (NM_001077411.2) was amplified from cDNA using primers containing restriction sites and a Kozak sequence in front of the start codon. The sequence encoding a hemagglutinin (HA) tag was added by PCR at the 3′-end. PCR products were subcloned either into pcDNA3.1 or pcDNA6 (Invitrogen) and their sequence was verified. mGBA2-HA was cloned into an expression vector that additionally expresses eGFP. For expression in E. coli, a His₆ tag was added to the 3′-end of mGBA2 and the construct was cloned into the pET21a vector (Novagen).

**Cell lines and culture**

Detailed information about the different cell lines used in this study can be found in Table 1. Cell lines from Gaucher and control patients were obtained from Coriell or from TeleThon (31). Mouse embryonic fibroblasts from wild-type and GBA1- or GBA2-deficient mice have been described elsewhere (13). Human fibroblasts were cultured in DMEM, 100 mM sodium pyruvate, 200 mM l-glutamine (all Thermo Fisher Scientific), 15% FCS (Biochrom); HAP1 cells were cultured in Iscove’s...
modified Dulbecco’s medium, 70 IU/penicillin, 70 μg/ml of streptomycin (all Thermo Fisher Scientific), 10% FCS; stable HEK293 cell lines were cultured in MEM, 1× non-essential amino acids, 1 mg/ml of G418 (all Thermo Fisher Scientific), 10% FCS; non-essential amino acids, 1 mg/ml of G418 and/or 0.01 mg/ml of blasticidin (all Thermo Fisher Scientific), 10% FCS. All cells were kept at 37 °C with 5 or 7.5% CO2. Cells were transfected using polyethylenimine (PEI, Sigma). The generation of stable cell lines is described elsewhere (13).

Mice

All animal experiments were conducted according to the German law of animal protection and in agreement with the approval of the local institutional animal care committees (Landesamt für Natur, Umwelt und Verbraucherschutz, North Rhine-Westphalia). Frozen brain tissue from wild-type and CBE-treated mice was obtained from the Futterman lab, Weizmann Institute of Science, Israel (15). Mice were maintained under specific pathogen-free conditions in the Experimental Animal Center of the Weizmann Institute of Science, and were handled according to protocols approved by the Weizmann Institute Animal Care Committee according to international guidelines. The generation of GBA2-deficient mice has been described elsewhere (32).

Antibodies

Antibodies are listed in Table 2. The polyclonal GBA2 antibody was generated by immunizing rabbits (experiments performed by Davids Biotechnology) with the full-length mGBA2 protein expressed in E. coli and purified from inclusion bodies (see below).

Purification of recombinant GBA2 from E. coli inclusion bodies to generate polyclonal antibodies

All steps were performed at 4 °C. Buffers contained protease inhibitor mixture Complete (Roche Life Science). Cells were re-suspended and lysed by sonication (3×30 s, Branson sonifier) in 50 mM Tris/HCl, pH 8.0, 200 μg/ml of lysozyme, DNase 1000 units/liter of culture, 500 mM NaCl, 5 mM MgCl2, and 1 mM DTT. After a 20-min incubation on ice, the suspension was centrifuged for 30 min at 11,000 × g and 4 °C. The pellet was re-suspended in solubilization buffer containing 1% Triton X-100 and 50 mM Tris/HCl, pH 8.0, 0.2 mM EDTA, and 1 mM DTT. The suspension was incubated by end-over-end rotation for 20 min and centrifuged for 15 min at 15,000 × g and 4 °C. The pellet containing the GBA2 inclusion bodies was re-extracted twice in the same way. GBA2 was solubilized from the inclusion bodies by sonication (3×30 s, Branson sonifier) in buffer L containing 20 mM imidazole, 20 mM sodium phosphate, 500 mM NaCl, 7 mM urea, pH 7.0, and loaded onto a CoCl2-activated HisTrap column (GE Healthcare Life Sciences) equilibrated with buffer L. The column was washed with 10 column volumes of buffer L. Recombinant GBA2 was eluted with buffer L containing 500 mM imidazole, collected, and concentrated to ~1.5 mg/ml using an Amicon Ultra-15 Centrifugal Filter Unit with Ultracel-50 membrane (Merck Millipore).

Affinity purification of polyclonal GBA2 antibody

Recombinant full-length GBA2 (1.5 mg) was loaded onto a 7.5% SDS gel using a SE400 electrophoresis unit (Hoefer). The gel slice containing mGBA2 was cut out and transferred to a PVDF membrane by Western blotting. The blot was incubated for 2 h with 20 ml of the final bleed (rabbit serum), which was diluted with 1 volume of TBS. The blot was washed consecutively with TBS, with TBS containing 0.05% Tween 20 (TBST), with 20 mM Tris/HCl, pH 7.4, and with 20 mM Tris/HCl, pH 7.4,
**Table 2**

| Antibodies | Species | Producer | Catalog No. | Dilution (Western blotting) |
|------------|---------|----------|-------------|----------------------------|
| Calnexin   | rb      | Sigma    | C4731       | 1:40,000 (tissue)           |
|            |         |          |             | 1:5,000–10,000 (cells)      |
| GRA1       | rb      | Sigma    | G4171       | 1:1,000                    |
| GRA1–2F8/4A12 mixture | rt | Körschens et al. (13) | |
| GFP        | rb      | Albcan   | ab6556      | 1:5,000                    |
| His tag    | ms      | Novagen  | 70796–3     | 1:1,000                    |
| β-Tubulin  | ms      | Sigma    | TUB 2.1     | 1:1,000                    |
| HA tag     | rt      | Roche    | 11867431001 | 1:5,000                    |
| GBA2–4/5   | rb      | —        | —           | 1:5,000                    |

**Secondary antibody**

| Species | Producer | Catalog No. | Dilution |
|---------|----------|-------------|----------|
| dk α ms IRDye680LT | LI-COR Biosciences | 926–68022 | 1:20,000 |
| dk α ms IRDye800CW | LI-COR Biosciences | 926–32212 | 1:20,000 |
| dk α rb IRDye680 | LI-COR Biosciences | 926–32223 | 1:20,000 |
| dk α rb IRDye800CW | LI-COR Biosciences | 926–32213 | 1:20,000 |
| gt α rt IRDye680 | LI-COR Biosciences | 926–32229 | 1:20,000 |
| gt α rt IRDye800CW | LI-COR Biosciences | 926–32219 | 1:20,000 |

Table 3

**Primers used for quantitative PCR**

| Gene Primer | Sequence (5’→3’) |
|-------------|------------------|
| hGBA1       | C1798 ACAGCCACACACATCCTCAG |
| hGBA2       | C1799 CXTATGGCCATTGCTTCTAGG |
| hB2m        | C1800 CXTATGCACTGGCTTCTAGG |
| hAlas1      | C1801 AGCTGCCAACGACGAACTG |
|            | C1818 CGAGCATCATATCAACCATCTC |
|            | C1819 CGAACCCTGCTACAGATACAC |
|            | C1824 AGCTTCACAGATGATGACAG |
|            | C1825 AGTCTTTCAGACATCCACTG |

**GBA2 in Gaucher disease**

500 mM NaCl. Acidic elution was performed by consecutive incubation with 0.1 M glycine at pH 2.5 and 1.9. Alkaline elution was next performed with 0.1 M triethylamine, pH 11.5. Acidic eluates were neutralized with 1 M Tris/HCl, pH 8.8, alkaline elutes with 1 M Tris/HCl, pH 7.4. Eluates were pooled and concentrated using an Amicon Ultra-15 Centrifugal Filter Unit with Ultracel-50 membrane (Merck Millipore) to produce antibody GBA2–4/5.

**Quantitative real-time PCR**

RNA was isolated using the NucleoSpinII columns (Macherey-Nagel) according to the manufacturer’s protocol. Reverse transcription was performed using SuperScript III (Thermo Scientific Fisher) and 2 μg of RNA. Quantitative real-time PCR was performed using SYBR Green (Bio-Rad) in a Bio-Rad iCycler with an IQ5 optical system. Primers are listed in Table 3. Data were analyzed using the Bio-Rad IQ5 optical system software and calculated according to the ΔΔC_{T} method (Bio-Rad Bulletin). After running the cycles, a melt-curve analysis was performed to detect nonspecifically amplified products. mRNA expression levels were normalized to the mean of the housekeeping genes (hB2m, hAlas1).

**Protein preparation**

All steps were performed at 4°C in the presence of a mammalian protease inhibitor mixture (mPIC, Sigma). Tissues were homogenized in hypotonic buffer (10 mM HEPES, 0.5 mM EDTA, pH 7.4: 0.1 g/ml wet weight) using an Ultra-turrax (IKA) and three pulses (20 s each) of sonication in ice-cold water (Branson sonifier). Tissue suspensions (total lysate) were subjected to low speed centrifugation for 20 min at 1,000 g. The supernatant (post-nuclear supernatant) was used for activity assays (13). Cultured cells were washed once with PBS and harvested using 1 ml of PBS/EDTA per 9-cm cell culture dish, and cells were pelleted for 5 min at 600 × g and 4 °C. Afterward, the pellets were directly lysed in hypotonic buffer, sonicated, and used for activity assays or Western blotting analysis. Proteins were de-glycosylated using peptide N-glycosidase F (New England Biolabs) according to the manufacturer’s protocol. Protein concentration was determined using the Bradford assay or the bicinchoninic acid (BCA) test kit (Pierce) according to the manufacturer’s protocol.

**Western blotting analysis**

Western blotting analysis was performed as described elsewhere (13, 33).

**β-Glucosidase activity assay**

The assay was performed as described elsewhere (13). In brief, the activity of cellular GBAs was analyzed using 4-MUG (Sigma) as a fluorescent substrate (1.67 mM final) at pH 4 and 6. Cleavage of 4-MUG was monitored in real-time in 384-well plates in a Fluostar Omega reader (BMG Labtech) at 29 °C using the filter pair 355 nm/460 nm for excitation and emission, respectively. To discriminate between GBA1 and GBA2 activity, CBE (Sigma), an inhibitor of GBA1 (34), or NB-DNJ (Sigma), an inhibitor of GBA2 (16), was included. The pH of the lysates and the 4-MUG solution was adjusted by diluting with McIlvaine buffer. We defined the activity of GBA1 as the CBE-blockable activity at pH 4 and the activity of GBA2 as the NB-DNJ-blockable activity at pH 6. The hydrolysis of 4-MUG was recorded as a change in relative fluorescence units per hour. Each analysis was performed as a quadruplicate in parallel.

**Treatments**

Cells on culture plate were treated with CBE (25 μM, C5424, Sigma), NB-DNJ (2 μM, Enzo Life Sciences, BML-SL230), or carmofur (2.9 mM, Cayman Chemical, number 14243) in culture medium at 37°C for 48 h before analyzing the β-glucosidase activity. As a control, the GBA2 activity in lysates from non-

---

*S. Schonauer, H. G. Körschen, and D. Wachten, unpublished data.*
treated cells was analyzed in the presence of 2.9 μM carmofur to exclude a direct effect on GBA2. To prepare lipid-BSA complexes, a 4 mg/ml of BSA solution was prepared in PBS, pH 7.4. The lipid stocks were diluted in the 4 mg/ml of BSA solution to the desired concentration. Lipid-BSA complexes were produced by sonication for 2 min (Branson sonifier), resulting in a milky suspension. The following lipids were used: sphingosine (Sigma, number 1802), sphinganine (Avanti Polar Lipids, number 860498P), FTY720 (Sigma, SML0700), sphingosine-1-phosphate (Avanti Polar Lipids, number 860492P), C6 ceramide (Enzo Life Sciences, BML-SL110), C8 ceramide (Enzo Life Sciences, BML-SL112), and C18 ceramide (Matreya LLC, number 1832). Cells were treated with lipid-BSA complexes diluted in culture medium containing only 1% FCS at 37 °C for 4.5 h. Hypotonic lysates were incubated with lipid-BSA complexes at room temperature for 1 h prior to analysis of β-glucosidase activity.

In vivo experiments

Treatment of mice with CBE has been described elsewhere (15). Frozen brains were taken from this study and used for the experiments presented here.

GBA2 expression in bacteria

Expression of pET21a-mGBA2-His was performed in the E. coli strain BL21 Codon Plus (DE3) RPL (Agilent Technologies, Santa Clara, CA) at 37 °C for 3 h after induction with 1 mM IPTG. mGBA2-His E. coli cultures were centrifuged for 10 min at 11,000 × g and 4 °C, and the pellet from a 30-ml culture was re-suspended in 4.8 ml of hypotonic buffer (1:8 dilution of the initial volume). The cell suspension was sonicated 3 × 20 s in ice-cold water (Branson sonifier) and 20 μl of the protein lysate were used per reaction, if not otherwise stated.

Preparation of membrane and soluble fractions for mass spectrometry

Cells were lysed in cold buffer A (10 mM NaCl, 25 mM HEPES, pH 7.5, 2 mM EDTA, 1:500 mPic) and incubated on ice for 15 min. The protein concentration was determined by BCA. To separate the soluble from the membrane fraction, samples were centrifuged for 30 min at 100,000 × g at 4 °C (TLA-55, Beckmann). The supernatant was transferred into a fresh tube and the membrane pellet was re-suspended in the same volume of buffer B (200 mM NaCl, 50 mM HEPES, pH 7.5, 1:500 mPic).

Quantification of sphingolipids by mass spectrometry

Cells were lysed in hypotonic lysis buffer and used for lipid extraction. Alternatively, the lysate was used for separation of membrane and soluble fractions as described above prior to lipid extraction. Lipids were extracted by adding 500 μl of chloroform/methanol/formic acid (1:1:0.1, v/v/v) and thorough mixing (33). At this point, internal standards were added (35). 250 μl of 1 M KCl, 0.2 M H3PO4 were added, samples were vortexed, and centrifuged at 5,000 rpm for 3 min to obtain phase separation. The lower phase containing the lipids was transferred to a fresh glass vial and the remaining samples were re-extracted by adding 500 μl of chloroform/methanol in a ratio of 2:1 (v/v). Samples were vortexed, centrifuged at 5,000 rpm for 3 min, and the lower phase was combined with the previous extract. Solvents were evaporated under N2 flow and lipids re-suspended in 500 μl of pure chloroform. Small silica columns (Strata-1-Silica, 55 μM, 70 Å containing 100 mg of silica) were equilibrated by flushing with pure chloroform for three times. Afterward, samples dissolved in pure chloroform were applied and non-polar lipids (e.g. triacylglycerol, sterols) were eluted with three column volumes of pure chloroform. Hexosylceramides, ceramides, glycosylated long chain bases (e.g. GlcSph), and free long chain bases were eluted with three column volumes of acetone/isopropyl alcohol (1:1, v/v). The acetone/isopropyl alcohol fraction was dried under N2 flow and dissolved in 100 μl of methanol. 50 μl of the sample were dried once more and dissolved in 100 μl of chloroform, methanol, 300 mM ammonium acetate (300:665:35, v/v/v) (36) and subjected to mass spectrometric analysis by nanospray direct infusion Q-TOF MS/MS as described elsewhere (33, 35). The remaining 50 μl of the sample were used for analysis of glycosylated long chain bases using LC-MS/MS with conditions as described elsewhere (37). The relative amounts of the glycosylated long chain bases were determined using d17:1-long chain base as internal standard.

Statistical analysis

Results are presented as mean ± S.D. Statistical analysis was performed using Origin Pro 9.0 (one-way analysis of variance). p values are only indicated when considered significant (≤0.05).

Author contributions—D. W. conceived and coordinated the study and wrote the paper. S. S. designed, performed, and analyzed the experiments and wrote the paper. H. G. K. generated and characterized antibodies and contributed to the design of the experiments, A. P., A. R., P. H., B. Br., B. Brugger, K. S., C. T., D. R., M. J. G., and A. H. F. contributed to the conception and design of the experiments, K. G. and P. D. performed and analyzed the lipid contents by mass spectrometry, and H. Z. and A. V. performed the CBE treatments of mice. All authors reviewed the results and approved the final version of the manuscript.

Acknowledgments—We thank J. H. Krause, S. Sonnenburg, D. Herborn, M. Völker, and J. Lux for technical assistance, Wolfgang Bönigk for cloning, and J. F. Jikeli for help with the analysis.

References

1. Brady, R. O., Kanfer, J. N., and Shapiro, D. (1965) Metabolism of glucocerebrosides: I. evidence of an enzymatic deficiency in Gaucher’s disease. Biochem. Biophys. Res. Commun. 18, 221–225.
2. Hruska, K. S., LaMarca, M. E., Scott, C. R., and Sidransky, E. (2008) Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum. Mutat. 29, 567–583.
3. Pastores, G. M. (1997) Gaucher’s disease: pathological features. Baillieres Clin. Haematol. 10, 739–749.
4. Futerman, A. H., and Zimran, A. (eds) (2006) Gaucher disease, CRC Press, Taylor and Francis Group, Boca Raton, FL.
5. Meivar-Levy, I., Horowitz, M., and Futerman, A. H. (1994) Analysis of glucocerebrosidase activity using N-(1-[14C]hexanoyl)-d-erythroglucosylsphingosine demonstrates a correlation between levels of residual enzyme activity and the type of Gaucher disease. Biochem. J. 303, 377–382.
6. Dekker, N., van Dussen, L., Hollak, C. E., Overkleeft, H., Scheij, S., Ghajarali, K., van Breeemen, M. J., Ferraz, M. J., Groener, J. E., Maas, M., April 14, 2017.
GBA2 in Gaucher disease

Wijburg, F. A., Speijer, D., Tykli-Szymanska, A., Mistry, P. K., Boot, R. G., and Aerts, J. M. (2011) Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. *Blood* **118**, e118–e127.

Ferraz, M. J., Marques, A. R., Gaspar, P., Miraizan, M., van Roomen, C., Ottenhoff, R., Alfonso, P., Iruin, P., Giraldo, P., Wisse, P., Sá Miranda, C., Overkleeft, H. S., and Aerts, J. M. (2016) Lyso-glycosphingolipid abnormalities in different murine models of lysosomal storage disorders. *Mol. Genet. Metab.* **117**, 186–193.

Korkotian, E., Schwarz, A., Pelled, D., Schwarzmann, G., Segal, M., and Futerman, A. H. (1999) Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons. *J. Biol. Chem.* **274**, 21673–21678.

Nilsson, O., and Svennerholm, L. (1982) Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease. *J. Neurochem.* **39**, 709–718.

Orvisky, E., Park, J. K., LaMarca, M. E., Ginn, E. I., Martin, B. M., Tayebi, N., and Sidransky, E. (2002) Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. *Mol. Genet. Metab.* **76**, 262–270.

Elleder, M. (2006) Glucosylceramide transfer from lysosomes: the missing link in molecular pathology of glucosylceramide deficiency: a hypothesis based on existing data. *J. Inherit. Metab. Dis.* **29**, 707–715.

Mistry, P. K., Liu, J., Sun, L., Chuang, W. L., Yuen, T., Yang, R., Lu, P., Zhang, K., Li, J., Keutzer, J., Stachnich, A., Mennone, A., Boyer, J. L., Jain, D., Brady, R. O., New, M. I., and Zaidi, M. (2014) Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease. *Proc. Natl. Acad. Sci. U.S.A.* **111**, 4934–4939.

Körshen, H. G., Yildiz, Y., Raju, D. N. D., Schonauer, S., Bönigk, W., Jansen, V., Kremmer, E., Kaupp, U. B., and Wachten, D. (2013) The non-lysosomal glucocerebrosidase GBA2 is a non-integral membrane-associated protein at the endoplasmic reticulum (ER) and Golgi. *J. Biol. Chem.* **288**, 3381–3393.

Farfel-Becker, T., Vitner, E. B., and Futerman, A. H. (2011) Animal models for Gaucher disease research. *Dis. Model Mech.* **4**, 746–752.

Vardi, A., Zigdon, H., Meshcheriakova, A., Klein, A. D., Yaacobi, C., Elam, R., Kenwood, B. M., Rahim, A. A., Massaro, G., Merrill, A. H., Jr., Vitner, E. B., and Futerman, A. H. (2016) Delineating pathological pathways in a chemically induced mouse model of Gaucher disease. *J. Pathol.* **239**, 496–509.

Ridley, C. M., Thr, K. E., Shanahan, J., Thillaiappan, N. B., Shen, A., Uhl, K., Walden, C. M., Rahim, A. A., Waddington, S. N., Platt, F. M., and van der Spoel, A. C. (2013) beta-Glucosidase GBA2 alters cytochrome c oxidase and increases the permeability of model and cell membranes. *J. Biol. Chem.* **288**, 7095–7101.

Burke, D. G., Rahim, A. A., Waddington, S. N., Karlsson, S., Enquist, I., Eckhardt, M., Sandhoff, R., Degen, J., Rabionet, M., Breiden, B., Sandhoff, K., Körshen, H. G., and Wachten, D. (2015) Accumulation of glucocerebroside in the absence of the beta-glucosidase 2 alters cytoskeletal dynamics. *PLoS Genet.* **11**, e1005063.

Legler, G., and Bieberich, E. (1988) Active site-directed inhibition of a cytosolic beta-glucosidase from calf liver by bromoconuridin B epoxide and bromoconuridin F. *Arch. Biochem. Biophys.* **260**, 437–442.

Ginkel, C., Hartmann, D., vom Dorp, K., Zlomuzica, A., Farwanah, H., Eckhardt, M., Sandhoff, R., Degen, J., Rabionet, M., Dörmann, P., Sandhoff, K., and Willecke, K. (2012) Ablation of neuronal ceramide synthase 1 in mice decreases ganglioside levels and expression of myelin-associated glycoprotein in oligodendrocytes. *J. Biol. Chem.* **287**, 4188–41902.

Welti, R., Li, W., Li, M., Sang, Y., Biesiadni, H., Zhou, H. E., Rajashekar, C. B., Williams, T. D., and Wang, X. (2002) Profiling membrane lipids in plant stress responses: role of phospholipase Dα in freezing-induced lipid changes in *Arabidopsis*. *J. Biol. Chem.* **277**, 31994–32002.

Scherer, M., Leuthäuser-Jaschinski, K., Ecker, J., Schmitz, G., and Liebsch, G. (2010) A rapid and quantitative LC-MS/MS method to profile sphingolipids. *J. Lipid Res.* **51**, 2001–2011.